Cristina Lage

C.W. Obel A/S is an investment company with a long history of investments and active ownership in Danish companies. The history of C.W. Obel A/S dates back to 1787 and today the company is fully owned by The Obel Family Foundation. C.W. Obel A/S owns 100% of the real estate company, C.W. Obel Ejendomme A/S, through which all real estate investments are made. C.W. Obel A/S continuously makes new direct investments focusing on good and healthy companies where C.W. Obel A/S can enter into a loyal and long-term partnership with the other owners as well as management. C.W. Obel A/S actively assists in the companies future value creation through additional growth capital and on-going strategic sparring with the companies stakeholders – for example in connection with succession planning, geographical expansion or the establishment of new activities. In addition to these strategic allocations, C.W. Obel A/S provides capital commitments to selected Danish and foreign Private Equity and Venture Capital funds as well as manages a liquid asset portfolio.

Topdanmark er et af landets største forsikringsselskaber. Vi er omkring 2.100 medarbejdere, der hjælper flere end 110.000 erhvervs- og landbrugskunder og 600.000 privatkunder på tværs af hele landet. Det har vi gjort siden 1898, hvor grundstenen til Topdanmark blev lagt. I mere end 100 år har vi hjulpet vores kunder med at passe på det, der betyder mest. Med at forebygge og begrænse skader. Til gavn for både mennesker og miljøet. Det gør os til en attraktiv virksomhed – ikke kun for vores kunder, men også for vores medarbejdere, aktionærer og verden omkring os.

LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 4,200 people, serving millions of patients across the world. In 2023, the company generated net sales of DKK 11.4 billion. Disclaimer: This site is intended for discussions about LEO Pharma and the various initiatives LEO Pharma is involved in. Due to regulations, discussions about pharmaceutical products are not allowed on this site. All content must be factual and non-promotional. LEO Pharma reserves the right to moderate or remove any content that may be inconsistent with legislation, industry ethics and regulations and LEO Pharma’s values, including: - profane or vulgar language - insulting or offensive comments, such as displays of racism, calls to violence, hate propaganda, etc. - commercial or political advertising - copyright infringements, or any violation of the rights of external parties - automatically-generated content i.e. spam - wrong/false statements For more information about our social media principles, please visit https://www.leo-pharma.com/social-media-principles